SusanGibbs(Gibbs)MooreMD

Oncology • Raleigh, NC

Physician

Join to view full profile

Dr. Moore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Moore's full profile

Already have an account?

Office
4420 Lake Boone Trl
Suite 200
Raleigh, NC 27607
Phone+1 919-784-6818

Fax+1 919-784-6826
Is this information wrong?

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2006
University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003
University of North Carolina at Chapel Hill School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2002 - Present
NC State Medical License 2006 - 2025
GA State Medical License 2003 - 2007

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

37 citations
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Daniel L. Hertz, Allison M. Deal, Joseph G. Ibrahim, Christine M. Walko, Karen E. Weck, Steven M. Anderson, Gustav Magrinat, Oludamilola Olajide, Susan E. Moore, Rache...> ;The Oncologist. 2016 Jul 1
39 citations
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven M. Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Sus...> ;British Journal of Clinical Pharmacology. 2015 Nov 1
150 citations
Geriatric Assessment-Identified Deficits in Older Cancer Patients With Normal Performance Status
Trevor A. Jolly, Allison M. Deal, Kirsten A. Nyrop, Grant R. Williams, Mackenzi Pergolotti, William A. Wood, Shani Alston, Brittaney Belle E. Gordon, Samara Ann Dixon,...> ;The Oncologist. 2015 Apr 1
5 citations
Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer
Noel T. Brewer, Jessica T. DeFrank, Wing Keung Chiu, Joseph G. Ibrahim, Christine M. Walko, Peter Rubin, Oludamilola Olajide, Susan G. Moore, Rachael E. Raab, Daniel R...> ;Public Health Genomics. 2014 Jan 1
25 citations
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
John W Tumeh, Pareen J. Shenoy, Susan G. Moore, John S. Kauh, Christopher R. Flowers> ;American Journal of Clinical Oncology. 2009 Feb 1
Development of query strategies to identify a histologic lymphoma subtype in a large linked database system.
Michael Graiser, Susan G Moore, Rochelle Victor, Ashley Hilliard, Leroy Hill, Michael S Keehan, Christopher R Flowers> ;Cancer Informatics. 2007 May 4
38 citations
Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy
Susan G. Moore, John W Tumeh, Steven Wojtanowski, Christopher R. Flowers> ;Value in Health. 2007 Jan 1
55 citations
Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.
John W Tumeh, Susan G. Moore, Rachel Shapiro, Christopher R. Flowers> ;Expert Review of Pharmacoeconomics & Outcomes Research. 2005 Apr 1
Join now to see all